Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study an important step for dog cancer therapy
dog lying down
Researchers investigated
the activation of genetic regulatory mechanisms in canine cell lines.
Researchers find similarities between human and canine cells

Scientists at the University of Veterinary Medicine, Vienna, are investigating molecular processes for targeted dog cancer therapy.

Modern cancer treatment has been revolutionised by the introduction of so-called 'targeted drugs'. However, the basis for applying these drugs in cancer therapy requires a deep understanding of the molecular mechanisms of the disease.

Now researchers have investigated an important process in the molecular genetics of cancer development in canine cells and found both similarities and differences, compared to those in humans.

In the study, the researchers investigated the activation of genetic regulatory mechanisms in canine cell lines. These cell lines have long been used by researchers to analyse pathological processes and were analysed for changes in the expression of several RNA-species.

So far, research on epithelial-mesenchyman transition (EMT) has focussed on cells of humans and mice, showing how certain pathways cooperate to allow cancer cells metastases.  Metastases form when the sedentary cancer cells gain certain properties. This allows them to move into another organ and form a new tumour.

Speaking to science news website phys.org, Mathias Muller, head of the institute for animal breeding and genetics, said:  "In the majority of cases it is the metastases that cost the patient's lives, as the original tumour can often be well controlled by radiation and surgery.

"We are interested in what is going on at the molecular level during metastasis, as it is likely that we can use this knowledge for the successful treatment of metastases."

It is well recognised that the transforming growth factor beta (TGF-beta) pathway plays a critical roll in metastasis.  Lead author Sabine Macho-Maschler expressed her satisfaction with the many similarities seen in the comparative analysis of results for canine, human and mouse cells.

"TGF-beta, for example, also plays an important role in dogs, but there are also interesting variations," she said. Her study is filled with  lists of RNAs that are regulated during EMT

The researchers say that the findings serve as a basis for further analysis. However, they are skeptical as to whether their research can improve the treatment of dogs with cancer in the near future.  

"Our newly published results are like a catalogue, perhaps an important requirement for new approaches and ideas. Ultimately, we do not even know whether many of the new drugs actually act in canine cells," said Sabine.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.